SHANGHAI, Nov. 8, 2024 /PRNewswire/ — On the morning of November 7, on the 7th China Worldwide Import Expo (CIIE), Henlius (2696.HK) entered right into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical (TASE:) Firm (“SVAX”), a subsidiary entity of Saudi Arabia’s distinguished household enterprise group within the healthcare sector, the Fakeeh Household. The 2 events will set up joint ventures in Saudi Arabia to combine Henlius’ main capabilities within the analysis, growth, and manufacturing of biologics with SVAX’s native experience in registration, market entry, and commercialization. The collaboration seeks to advance the worldwide registration and commercialization of a number of Henlius merchandise and improve the accessibility of superior biologics throughout the Center East, North Africa, and Türkiye (MENAT) nations, and profit extra sufferers.
The signing ceremony was attended by Ms. Weilai Shen, Director of the Overseas Financial Cooperation Division of the Shanghai Municipal Fee of Commerce, Mr. Gang Ling, The Science and Economic system Fee of the Folks’s Authorities of Shanghai Pudong New Space, Mr. Qiyu Chen, Co-CEO of Fosun Worldwide, Mr. Yifang Wu, Chairman of Fosun Pharma, Mr. Wenjie Zhang, Government President of Fosun Pharma and Chairman of Henlius, Mr. Ammar Fakeeh, Chairman of the Household Enterprise, and Prof. Mazen M. Hassanain, Founder and Managing Director of SVAX.
In keeping with the settlement, Henlius and SVAX will set up joint ventures for commercialization and manufacturing in Saudi Arabia and can collaborate on a sequence of Henlius merchandise within the MENAT area, together with HANDAYUAN (adalimumab, HLX03) and HANBEITAI (bevacizumab, HLX04), to conduct native business and manufacturing actions. As well as, the 2 events will initially concentrate on collectively investing within the growth of Henlius’ investigational biosimilar of pembrolizumab, HLX17, to speed up its international registration and commercialization.
Mr. Wenjie Zhang, Government President of Fosun Pharma and Chairman of Henlius, acknowledged, “Our collaboration with SVAX is a crucial step in Henlius’ global blueprint, strengthening our presence in key markets while enhancing our international competitiveness. Through this partnership, we aim to drive innovation and growth for both parties, advance the research and manufacturing of high-quality biologics, and deliver more affordable therapies to patients in MENAT countries, thereby contributing to the global healthcare initiative. “
Dr. Jason Zhu, CEO of Henlius, stated, “We are delighted to collaborate with SVAX. This partnership not only complements our global strategy but also reaffirms our commitment to ‘patient-centered’ care. SVAX’s dedication to innovation and improving regional healthcare closely aligns with Henlius’ mission. Together, by combining SVAX’s extensive resources and local expertise in MENAT with Henlius’ global outlook and innovative capabilities, we are poised to bring more high-quality, innovative biologics to patients across the region and beyond.”
Mr. Ammar Fakeeh, Chairman of the Household Enterprise, acknowledged, “We are honored to forge this strategic partnership with Henlius, whose excellence in biopharmaceutical innovation perfectly complements our mission to elevate healthcare in the MENAT region. By joining forces, we are enhancing access to essential, high-quality biologics and strengthening the foundations of a resilient healthcare ecosystem in Saudi Arabia and beyond. This collaboration represents an important step forward in delivering advanced therapies to patients, embodying our commitment to health, innovation, and sustainable impact.”
Prof. Mazen Hassanain, Founder and Managing Director of SVAX, acknowledged, “We at SVAX are delighted to enter this strategic partnership with Henlius, a company known for its commitment to high-quality and innovative biologic medicines. Combining our knowledge and experience in regulatory, marketing, sales, and local manufacturing with Henlius’ expertise in biopharmaceutical development and global supply, we aim to bring cutting-edge therapies to the MENAT region and impact patients’ lives. This partnership aligns with our dedication to advancing healthcare in the Kingdom (TADAWUL:) of Saudi Arabia and beyond, fostering an ecosystem where life-changing therapies are accessible to those who need them. Together with Henlius, we look forward to driving growth, innovation, and healthcare accessibility across the region.”
As a worldwide, progressive biopharmaceutical firm, Henlius is devoted to providing high-quality, inexpensive, and progressive biologic medicines for sufferers worldwide, specializing in oncology, autoimmune ailments, and ophthalmic ailments. Henlius constantly enhances the event and operational effectivity of its built-in R&D, manufacturing, and commercialization platform. By means of varied measures to enhance product accessibility, the corporate drives the business progress of core merchandise and achieves sustained high-quality profitability. Henlius has proactively constructed a diversified, high-quality product pipeline overlaying over 50 molecules. Six merchandise have been launched in China, three have been accredited for advertising and marketing in abroad markets, and 24 indications are accredited worldwide, benefiting over 670,000 sufferers. Particularly, HANQUYOU (trastuzumab, commerce identify: HERCESSI™ within the U.S. and Zercepac ® in Europe) has been accredited in 49 nations and areas globally, making it the China-developed mAb biosimilar with probably the most advertising and marketing approvals and benefiting over 215,000 sufferers with breast and gastric most cancers. Henlius collaborates with worldwide companions to advertise China’s biopharmaceutical innovation and advance international growth, with a presence throughout Asia, Europe, Latin America, North America, and Oceania.
The MENAT area represents a big a part of the worldwide pharmaceutical market. With rising healthcare wants and supportive authorities insurance policies, the biopharmaceutical business within the space is witnessing a speedy transformation. In June 2024, Zercepac ® efficiently shipped to Saudi Arabia, turning into the primary China-developed monoclonal antibody (mAb) to enter the Center Jap market. The sturdy tie between Henlius and SVAX will assist obtain joint growth for the 2 events and foster pharmaceutical innovation in rising markets. Henlius stays dedicated to enhancing its international competitiveness, assembly international scientific wants, and spurring biopharmaceutical innovation.
About SVAX
SVAX is a pioneering Saudi firm with a mission to localizing biomanufacturing inside Saudi Arabia and guaranteeing a gentle, high-quality provide of vaccines and biologics for the area. Established to bolster nationwide well being safety, SVAX actively helps the area’s preparedness for pandemics towards infectious ailments. Aligned with Saudi Imaginative and prescient 2030 and the Saudi Nationwide Biotechnology Technique, the corporate is on the forefront of nationalizing the biomanufacturing sector by using extremely expert Saudi scientists and professionals.
SVAX is distinguished as an area developer and producer of important biologics that serves Saudi Arabia and the broader MENAT area. The corporate operates via three strategic enterprise segments: innovation, manufacturing, and advisory providers. Its innovation efforts are centered on superior R&D in biologics and vaccines, driving ahead innovation and collaboration to deliver cutting-edge therapies to market. In manufacturing, SVAX is establishing a state-of-the-art applied sciences and amenities to supply vaccines and biologics that meet international requirements. In the meantime, via its advisory providers, SVAX affords knowledgeable consulting to assist and speed up the event of a robust biotech business throughout the area.
By means of these initiatives, SVAX is uniquely positioned to drive transformative change in biomanufacturing, guaranteeing that the area stays resilient, progressive, and ready for future healthcare challenges.
About Henlius
Henlius (2696.HK) is a worldwide biopharmaceutical firm with the imaginative and prescient to supply high-quality, inexpensive, and progressive biologic medicines for sufferers worldwide with a concentrate on oncology, autoimmune ailments, and ophthalmic ailments. Updated, 6 merchandise have been launched in China, 3 have been accredited for advertising and marketing in abroad markets, 24 indications are accredited worldwide, and 4 advertising and marketing functions have been accepted for evaluation in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has constructed an built-in biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded all through the entire product life cycle together with R&D, manufacturing and commercialization. It has established international innovation centre and Shanghai-based business manufacturing amenities certificated by China, the EU and U.S. GMP.
Henlius has pro-actively constructed a diversified and high-quality product pipeline overlaying over 50 molecules and has continued to discover immuno-oncology mixture therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as spine. Aside from the launched merchandise HANLIKANG (rituximab), the primary China-developed biosimilar, HANQUYOU (trastuzumab, commerce identify: HERCESSI™ within the U.S., Zercepac ® in Europe), a China-developed mAb biosimilar accredited in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab) and HANNAIJIA (neratinib), the progressive product HANSIZHUANG has been accredited by the NMPA for the remedy of MSI-H strong tumours, squamous non-small cell lung most cancers (sqNSCLC) and extensive-stage small cell lung most cancers (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the first-line remedy of SCLC. What’s extra, Henlius has carried out over 30 scientific research for 16 merchandise, increasing its presence in main markets in addition to rising markets.
